About Inotec AMD

Inotec AMD is a Cambridge based company that was formed specifically to introduce a new technology to wound care specialists and health care providers around the world. NATROX® Oxygen Wound Therapy was designed to promote faster and better healing in patients with wounds.

Non Executive Directors

Dr Adrian Parton MBE

Adrian Parton is a Director of Objective Imaging Ltd (Hardware Software Automation business), AB-Polyblok Ltd (novel dementia drug), Toxibact Ltd (Novel antimicrobial) and Chairman/Owner of Ivy House Country House Hotel. He has a PhD in Molecular Virology and has been in industry for the last 25 years. He has successfully grown technology based businesses from concept through to production and into multi-national businesses.

Luigi Sala
Non-executive Director

Luigi Sala is Partner and Chairman with Charme Capital Partners, a private equity firm investing in management buy outs throughout Europe and the UK. He is also a passionate business angel in healthcare start ups.

Pierre Socha
Non-executive Director

Pierre Socha is an early stage technology investor with Amadeus Capital Partners. He invests in digital health, medical technologies, autonomous systems, augmented reality, cyber security and artificially intelligence. He currently sits on the boards of Doctify, Repositive, Lumeon, PhoreMost and Congenica.

Michael Clancy
Non-executive Director

Michael Clancy has 35 years’ experience in marketing, sales and general management within European medical devices with specialist knowledge and experience within the medical beds, pressure redistribution and wound care sectors. He is currently non-executive director at Medstrom Ltd and Inotec AMD Limited.


Cambridge Capital Group

Cambridge Capital Group is a leading business angel group of 40 investors that have been investing in hi-tech businesses for ten years.

Cambridge Enterprise

Cambridge Enterprise Limited is a wholly owned subsidiary of the University of Cambridge, responsible for the commercialisation of University intellectual property.

Cambridge Angels

The Cambridge Angels are a group of high-net worth investors who have proven experience as successful entrepreneurs in technology and bio-technology.

Amadeus Capital Partners

Amadeus Capital Partners is a global technology investor. Since its inception in 1997, the firm has raised over $1bn for investment and backed more than 100 companies in the software, mobile, internet, cyber security and medical technology sectors. The investment team is based in India, South Africa, Sweden, UK and USA, has deep experience in technology and invests in high-growth companies from early stage to pre-IPO.

Information for clinicians

Oxygen is critical to many of the processes required in wound healing. NATROX® Oxygen Wound Therapy allows you to prescribe topical oxygen in a very simple, safe and extremely convenient way directly to the wound bed.

Read more

Information for patients

NATROX® Oxygen Wound Therapy is a small portable device about the size of a mobile phone. Its function is to produce concentrated oxygen from the surrounding air, and pass this down a thin flexible tube directly to a wound that is failing to progress as expected.

Read more

Inotec AMD’s mission is to improve the quality of life for patients with chronic wounds by providing NATROX® an innovative topical oxygen therapy. Our culture is derived from a passion for medicine, compassion for patients, respect among employees and a commitment to all our internal and external customers.

Craig Kennedy CEO
Craig Kennedy

Innovative wound care treatment

In a communications initiative with New NHS Alliance and ITN Productions, NATROX® Oxygen Wound Therapy was featured in their campaign to promote “Healthy Communities, Healthy People”.

More News